N4 Pharma is a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle, Nuvec®, has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.
The company was established in 2014 by Nigel Theobald, previously head of healthcare brands at Boots Group plc and founder of a series of successful businesses, including Oxford Pharmascience Group plc. Joining Nigel on N4 Pharma’s Board are Dr John Chiplin, who has significant operational, investment and transaction experience in the life science and technology industries, Dr David Templeton, pharmacology and pre-clinical drug discovery expert, Dr Chris Britten, an experienced pharmaceutical executive and Luke Cairns, Corporate Financier.
N4 Pharma added to its R&D team in 2018 with the appointments of Dr Allan Hey as Head of Nuvec® CMC Program Development and Dr Melody Janssen as a Consultant for the Nuvec® biological research program.